| Symbol | TGTX |
|---|---|
| Name | TG THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2 GANSEVOORT STREET,9TH FLOOR, NEW YORK, New York, 10014, United States |
| Telephone | +1 212 554-4484 |
| Fax | — |
| — | |
| Website | https://www.tgtherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001001316 |
| Description | TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. Additional info from NASDAQ: |
2026-08-07 21:00
Director Charney Laurence N 🔴 sold 6.0K shares of TG THERAPEUTICS, INC. (TGTX) Transaction Date: Aug 06, 2026 | Filing ID: 026608
Read more
2026-07-29 11:30
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
Read more
2026-07-21 21:20
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
Read more
2026-07-06 11:30
TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
Read more
2026-06-15 21:03
Director Lonial Sagar 🟢 acquired 8.3K shares (1 derivative) of TG THERAPEUTICS, INC. (TGTX) Transaction Date: Jun 11, 2026 | Filing ID: 020679
Read more
2026-06-15 21:02
Director HUME DANIEL 🟢 acquired 8.3K shares (1 derivative) of TG THERAPEUTICS, INC. (TGTX) Transaction Date: Jun 11, 2026 | Filing ID: 020677
Read more
2026-06-15 21:02
Director Hoberman Kenneth 🟢 acquired 8.3K shares (1 derivative) of TG THERAPEUTICS, INC. (TGTX) Transaction Date: Jun 11, 2026 | Filing ID: 020676
Read more
2026-06-15 21:01
Director Echelard Yann 🟢 acquired 8.3K shares (1 derivative) of TG THERAPEUTICS, INC. (TGTX) Transaction Date: Jun 11, 2026 | Filing ID: 020675
Read more
2026-06-15 21:00
Director Charney Laurence N 🟢 acquired 8.3K shares (1 derivative) of TG THERAPEUTICS, INC. (TGTX) Transaction Date: Jun 11, 2026 | Filing ID: 020673
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07577583 | Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel | — | B-cell Mediated Autoimmune Disorders | Not_Yet_Recruiting | 2027-05-01 | 2039-12-01 | ClinicalTrials.gov |
| NCT07673744 | A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Followin… | Phase2 | Myasthenia Gravis | Recruiting | 2026-07-30 | 2030-01-01 | ClinicalTrials.gov |
| NCT07680946 | Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With S… | Phase2 | Schizophrenia | Recruiting | 2026-07-03 | 2029-03-01 | ClinicalTrials.gov |
| NCT07220252 | Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing… | Phase2 | Relapsing Multiple Sclerosis | Recruiting | 2026-07-01 | 2033-06-30 | ClinicalTrials.gov |
| NCT06864936 | Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Respon… | Na | Multiple Sclerosis (MS) - Relapsing-remitting | Recruiting | 2026-05-01 | 2028-01-30 | ClinicalTrials.gov |
| NCT07503873 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublit… | Phase2 | Multiple Sclerosis | Recruiting | 2026-04-01 | 2029-05-30 | ClinicalTrials.gov |
| NCT07389590 | Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis | Phase4 | Multiple Sclerosis | Recruiting | 2026-02-10 | 2029-03-01 | ClinicalTrials.gov |
| NCT07225361 | Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis | Phase4 | Multiple Sclerosis | Recruiting | 2025-11-28 | 2029-08-01 | ClinicalTrials.gov |
| NCT07211633 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiologica… | Phase3 | Relapsing Multiple Sclerosis | Active_Not_Recruiting | 2025-07-09 | 2028-12-31 | ClinicalTrials.gov |
| NCT06680037 | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants … | Phase1 | B-cell Mediated Autoimmune Disorders | Recruiting | 2025-05-06 | 2030-01-01 | ClinicalTrials.gov |
| NCT06433752 | A Study Evaluating the Real World Experience of Participants Treated With BRIUM… | — | Relapsing Multiple Sclerosis | Recruiting | 2024-07-22 | 2032-04-01 | ClinicalTrials.gov |
| NCT06433765 | A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant… | — | Multiple Sclerosis | Recruiting | 2024-06-01 | 2035-03-31 | ClinicalTrials.gov |
| NCT06143514 | A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in … | — | Relapsing Multiple Sclerosis | Recruiting | 2024-03-26 | 2026-10-31 | ClinicalTrials.gov |
| NCT05877963 | Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regi… | Phase3 | Relapsing Multiple Sclerosis | Recruiting | 2023-06-13 | 2027-12-01 | ClinicalTrials.gov |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Ce… | Phase1 | CLL | Terminated | 2021-04-28 | 2024-06-12 | ClinicalTrials.gov |
| NCT04149821 | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2021-02-10 | 2022-06-09 | ClinicalTrials.gov |
| NCT04624633 | Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | Phase2 | Chronic Lymphocytic Leukemia | Active_Not_Recruiting | 2020-12-15 | 2028-01-01 | ClinicalTrials.gov |
| NCT04130997 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Scler… | Phase3 | Relapsing Multiple Sclerosis (RMS) | Active_Not_Recruiting | 2019-11-18 | 2032-05-31 | ClinicalTrials.gov |
| NCT04163718 | TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leuk… | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2019-11-12 | 2022-10-19 | ClinicalTrials.gov |
| NCT03776864 | Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory C… | Phase2 | Hodgkin's Lymphoma | Terminated | 2019-09-26 | 2021-09-14 | ClinicalTrials.gov |
| NCT04016805 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Partic… | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2019-08-05 | 2022-05-22 | ClinicalTrials.gov |
| NCT03828448 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïv… | Phase2 | Follicular Lymphoma | Terminated | 2019-07-10 | 2022-05-31 | ClinicalTrials.gov |
| NCT03801525 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbr… | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2019-05-16 | 2022-12-20 | ClinicalTrials.gov |
| NCT03778073 | Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma | Phase1 | B-cell Non Hodgkin Lymphoma | Terminated | 2019-04-17 | 2022-08-01 | ClinicalTrials.gov |
| NCT03804996 | Study of TG-1801 in Subjects With B-Cell Lymphoma | Phase1 | B-Cell Lymphoma | Completed | 2019-03-05 | 2024-02-21 | ClinicalTrials.gov |
| NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patien… | Phase1 | Non Hodgkin Lymphoma | Terminated | 2018-09-10 | 2024-05-21 | ClinicalTrials.gov |
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab … | Phase1 | Chronic Lymphocytic Leukemia | Terminated | 2018-03-27 | 2022-06-16 | ClinicalTrials.gov |
| NCT03364231 | Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-… | Phase2 | Marginal Zone Lymphoma | Completed | 2017-11-30 | 2022-02-15 | ClinicalTrials.gov |
| NCT03277261 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Rel… | Phase3 | Relapsing Multiple Sclerosis (RMS) | Completed | 2017-09-19 | 2020-11-06 | ClinicalTrials.gov |
| NCT03277248 | Study to Assess the Efficacy and Safety of Ublituximab in Participants With Rel… | Phase3 | Relapsing Multiple Sclerosis (RMS) | Completed | 2017-08-25 | 2020-11-12 | ClinicalTrials.gov |
| NCT03178201 | TGR1202 in Relapsed and Refractory Follicular Lymphoma | Phase2 | Follicular Lymphoma | Terminated | 2017-08-20 | 2020-06-30 | ClinicalTrials.gov |
| NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents … | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2017-08-09 | 2022-06-24 | ClinicalTrials.gov |
| NCT03381170 | An Extension of the TG1101-RMS201 Trial | Phase2 | Relapsing Remitting Multiple Sclerosis | Completed | 2017-06-01 | 2022-11-11 | ClinicalTrials.gov |
| NCT02738775 | Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple… | Phase2 | Multiple Sclerosis | Completed | 2016-05-27 | 2018-08-13 | ClinicalTrials.gov |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Wit… | Phase2 | Diffuse Large B-Cell Lymphoma | Terminated | 2016-05-25 | 2022-07-04 | ClinicalTrials.gov |
| NCT02742090 | Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymph… | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2016-04-21 | 2021-06-10 | ClinicalTrials.gov |
| NCT02656303 | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With … | Phase2 | Chronic Lymphocytic Leukemia | Terminated | 2016-01-07 | 2022-07-11 | ClinicalTrials.gov |
| NCT02612311 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants … | Phase3 | Chronic Lymphocytic Leukemia | Terminated | 2015-11-19 | 2023-02-22 | ClinicalTrials.gov |
| NCT02535286 | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patien… | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2015-09-18 | 2021-11-04 | ClinicalTrials.gov |
| NCT02574663 | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or W… | Phase1 | Pancreatic Cancer | Completed | 2015-09-11 | 2018-08-01 | ClinicalTrials.gov |
| NCT02301156 | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participant… | Phase3 | Chronic Lymphocytic Leukemia | Completed | 2015-01-27 | 2020-04-01 | ClinicalTrials.gov |
| NCT02268851 | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and… | Phase1 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Completed | 2014-11-01 | 2022-10-01 | ClinicalTrials.gov |
| NCT02164006 | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin fo… | Phase1 | Hodgkin's Lymphoma | Completed | 2014-06-11 | 2016-05-01 | ClinicalTrials.gov |
| NCT02100852 | TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chloramb… | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2014-03-12 | 2017-11-01 | ClinicalTrials.gov |
| NCT02013128 | Ublituximab + Ibrutinib in Select B-cell Malignancies | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2014-01-06 | 2015-12-01 | ClinicalTrials.gov |
| NCT02006485 | Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patie… | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2013-12-13 | 2019-10-01 | ClinicalTrials.gov |
| NCT01767766 | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refra… | Phase1 | Non-Hodgkin's Lymphoma | Completed | 2013-01-07 | 2018-02-01 | ClinicalTrials.gov |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid M… | Phase1 | Non-Hodgkins Lymphoma | Terminated | 2012-11-21 | 2014-02-07 | ClinicalTrials.gov |
| NCT01647971 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Re… | Phase1 | Non-Hodgkins Lymphoma | Completed | 2012-07-19 | 2015-05-01 | ClinicalTrials.gov |
Total clinical trials: 49
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Other disease modifying therapies | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ublituximab | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ublituximab | Other | Phase PHASE2 | Schizophrenia | RECRUITING | NCT07680946 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| No intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06143514 |
| No Intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| Prefilled pen | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT07503873 |
| Ublituximab | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT07503873 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT07673744 |
| Ublituximab | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT07673744 |
| Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING | NCT04130997 |
| No intervention | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT06433765 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT07211633 |
| Fingolimod | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | RECRUITING | NCT07220252 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | RECRUITING | NCT07220252 |
| Ublituximab | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | RECRUITING | NCT07220252 |
| Fingolimod | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | RECRUITING | NCT07220252 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | RECRUITING | NCT07220252 |
| Ublituximab | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | RECRUITING | NCT07220252 |
| AI device | Device | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT07503873 |
| Ublituximab | Other | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT07503873 |
| Ublituximab | Other | Phase PHASE2 | Schizophrenia | NOT_YET_RECRUITING | NCT07680946 |
| Placebo | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT07673744 |
| Ublituximab | Other | Phase PHASE2 | Myasthenia Gravis | RECRUITING | NCT07673744 |
| Fingolimod | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Ublituximab | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| No intervention | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT06433765 |
| No intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06143514 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT07211633 |
| No Intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING | NCT04130997 |
| No Intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING | NCT04130997 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT07211633 |
| Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT07211633 |
| No Intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT07211633 |
| No Intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT07211633 |
| No Intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT07211633 |
| No Intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT07211633 |
| No Intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| No intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06143514 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT07211633 |
| No Intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING | NCT04130997 |
| No intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06143514 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT07211633 |
| No Intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING | NCT04130997 |
| No intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06143514 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING | NCT07211633 |
| No Intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING | NCT04130997 |
| No intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06143514 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING | NCT04130997 |
| No intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06143514 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING | NCT04130997 |
| No intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06143514 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING | NCT04130997 |
| No intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06143514 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING | NCT04130997 |
| No intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06143514 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING | NCT04130997 |
| No intervention | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT06433765 |
| Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Fingolimod | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Ublituximab | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| No intervention | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT06433765 |
| Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Fingolimod | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Ublituximab | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| No intervention | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT06433765 |
| Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Fingolimod | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Ublituximab | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| No intervention | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT06433765 |
| Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Fingolimod | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Ublituximab | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| No intervention | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT06433765 |
| Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Fingolimod | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Ublituximab | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| No intervention | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT06433765 |
| No Intervention | Other | Preclinical | B-cell Mediated Autoimmune Disorders | NOT_YET_RECRUITING | NCT07577583 |
| Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Fingolimod | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Placebo | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Ublituximab | Other | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| No Intervention | Other | Preclinical | B-cell Mediated Autoimmune Disorders | NOT_YET_RECRUITING | NCT07577583 |
| No Intervention | Other | Preclinical | B-cell Mediated Autoimmune Disorders | NOT_YET_RECRUITING | NCT07577583 |
| No Intervention | Other | Preclinical | B-cell Mediated Autoimmune Disorders | NOT_YET_RECRUITING | NCT07577583 |
| No Intervention | Other | Preclinical | B-cell Mediated Autoimmune Disorders | NOT_YET_RECRUITING | NCT07577583 |
| No Intervention | Other | Preclinical | B-cell Mediated Autoimmune Disorders | NOT_YET_RECRUITING | NCT07577583 |
| Other disease modifying therapies | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ublituximab | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ocrelizumab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Ublituximab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Ocrelizumab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Ublituximab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Other disease modifying therapies | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ublituximab | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ocrelizumab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Ublituximab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Other disease modifying therapies | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ublituximab | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ocrelizumab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Ublituximab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Other disease modifying therapies | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ublituximab | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ocrelizumab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Ublituximab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Other disease modifying therapies | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ublituximab | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ocrelizumab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Ublituximab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Other disease modifying therapies | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ublituximab | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ocrelizumab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Ublituximab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Other disease modifying therapies | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ublituximab | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ocrelizumab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Ublituximab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Other disease modifying therapies | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ublituximab | Other | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | RECRUITING | NCT06864936 |
| Ocrelizumab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Ublituximab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07389590 |
| Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02574663 |
| Oxaliplatin + Folinic acid + Fluorouracil | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02574663 |
| nab-paclitaxel + gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02574663 |
| TGR-1202 | Other | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02574663 |
| TGR-1202 + brentuximab vedotin | Other | Phase PHASE1 | Hodgkin's Lymphoma | COMPLETED | NCT02164006 |
| TGR-1202 + Obinutuzumab + Chlorambucil | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02100852 |
| Ublituximab + TGR-1202 + bendamustine | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02006485 |
| Ublituximab + TGR-1202 + ibrutinib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02006485 |
| Ublituximab + TGR-1202 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02006485 |
| Placebo | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT02738775 |
| Ublituximab | Other | Phase PHASE2 | Multiple Sclerosis | COMPLETED | NCT02738775 |
| TGR-1202 | Other | Phase PHASE2 | Follicular Lymphoma | TERMINATED | NCT03178201 |
| TGR-1202 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma | COMPLETED | NCT01767766 |
| IV Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | COMPLETED | NCT03277261 |
| Oral Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | COMPLETED | NCT03277261 |
| Teriflunomide | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | COMPLETED | NCT03277261 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | COMPLETED | NCT03277261 |
| IV Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | COMPLETED | NCT03277248 |
| Oral Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | COMPLETED | NCT03277248 |
| Teriflunomide | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | COMPLETED | NCT03277248 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | COMPLETED | NCT03277248 |
| Lenalidomide | Other | Phase PHASE1 | Non-Hodgkins Lymphoma | TERMINATED | NCT01744912 |
| Ublituximab | Other | Phase PHASE1 | Non-Hodgkins Lymphoma | TERMINATED | NCT01744912 |
| Ibrutinib | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02301156 |
| Ublituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02301156 |
| TGR-1202 + Ublituximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT03207256 |
| TGR-1202 | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT03207256 |
| Bendamustine | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma | TERMINATED | NCT02793583 |
| Umbralisib | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma | TERMINATED | NCT02793583 |
| Ublituximab | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma | TERMINATED | NCT02793583 |
| Cosibelimab + Ublituximab + Bendamustine combination | Other | Phase PHASE1 | B-cell Non Hodgkin Lymphoma | TERMINATED | NCT03778073 |
| Cosibelimab | Other | Phase PHASE1 | B-cell Non Hodgkin Lymphoma | TERMINATED | NCT03778073 |
| Lenalidomide | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT03379051 |
| Ublituximab | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT03379051 |
| Umbralisib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT03379051 |
| Venetoclax | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT03379051 |
| TG-1501 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02535286 |
| ublituximab | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02535286 |
| Umbralisib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02535286 |
| Ibrutinib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02013128 |
| Ublituximab | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02013128 |
| Ublituximab | Other | Phase PHASE1 | Non-Hodgkins Lymphoma | COMPLETED | NCT01647971 |
| Ublituximab | Other | Phase PHASE2 | Relapsing Remitting Multiple Sclerosis | COMPLETED | NCT03381170 |
| Umbralisib | Other | Phase PHASE2 | Hodgkin's Lymphoma | TERMINATED | NCT03776864 |
| Pembrolizumab | Other | Phase PHASE2 | Hodgkin's Lymphoma | TERMINATED | NCT03776864 |
| Ublituximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT04149821 |
| Umbralisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT04149821 |
| Umbralisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT02656303 |
| Ublituximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT02656303 |
| Umbralisib | Other | Phase PHASE2 | Marginal Zone Lymphoma | COMPLETED | NCT03364231 |
| Acalabrutinib Oral Capsule | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT04016805 |
| Venetoclax | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT04016805 |
| Ibrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT04016805 |
| Umbralisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT04016805 |
| Ublituximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT04016805 |
| Umbralisib | Other | Phase PHASE2 | Follicular Lymphoma | TERMINATED | NCT03828448 |
| Ublituximab | Other | Phase PHASE2 | Follicular Lymphoma | TERMINATED | NCT03828448 |
| Ublituximab | Other | Phase PHASE1 | B-Cell Lymphoma | COMPLETED | NCT03804996 |
| TG-1801 | Other | Phase PHASE1 | B-Cell Lymphoma | COMPLETED | NCT03804996 |
| Venetoclax | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT03801525 |
| Umbralisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT03801525 |
| Ublituximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT03801525 |
| Umbralisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT02742090 |
| Ublituximab | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT03671590 |
| Umbralisib | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT03671590 |
| TG-1701 | Other | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT03671590 |
| Ublituximab | Other | Phase PHASE1 | CLL | TERMINATED | NCT04806035 |
| TG-1801 | Other | Phase PHASE1 | CLL | TERMINATED | NCT04806035 |
| Ibrutinib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | COMPLETED | NCT02268851 |
| TGR-1202 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | COMPLETED | NCT02268851 |
| Chlorambucil | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT02612311 |
| TGR-1202 | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT02612311 |
| Ublituximab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT02612311 |
| Obinutuzumab | Other | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT02612311 |
| No Intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| Umbralisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT04163718 |
| Ocrelizumab | Other | Phase PHASE4 | Multiple Sclerosis | NOT_YET_RECRUITING | NCT07389590 |
| Ublituximab | Other | Phase PHASE4 | Multiple Sclerosis | NOT_YET_RECRUITING | NCT07389590 |
| Ublituximab | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04624633 |
| Umbralisib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04624633 |
| Acalabrutinib | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04624633 |
| Ublituximab | Other | Phase PHASE4 | Multiple Sclerosis | RECRUITING | NCT07225361 |
| AI Device | Device | Phase PHASE2 | Multiple Sclerosis | NOT_YET_RECRUITING | NCT07503873 |
| Ublituximab | Other | Phase PHASE2 | Multiple Sclerosis | NOT_YET_RECRUITING | NCT07503873 |
| Placebo | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT05877963 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis | RECRUITING | NCT07211633 |
| No intervention | Other | Preclinical | Multiple Sclerosis | RECRUITING | NCT06433765 |
| Azercabtagene zapreleucel (azer-cel) | Other | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| No intervention | Other | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06143514 |
| Ublituximab | Other | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING | NCT04130997 |
| AI Device | DEVICE | Phase PHASE2 | Multiple Sclerosis | NOT_YET_RECRUITING | NCT07503873 |
| Ocrelizumab | DRUG | Phase PHASE4 | Multiple Sclerosis | NOT_YET_RECRUITING | NCT07389590 |
| Fingolimod | DRUG | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Other disease modifying therapies | OTHER | Approved | Multiple Sclerosis (MS) - Relapsing-remitting | NOT_YET_RECRUITING | NCT06864936 |
| Azercabtagene zapreleucel (azer-cel) | DRUG | Phase PHASE1 | B-cell Mediated Autoimmune Disorders | RECRUITING | NCT06680037 |
| No Intervention | OTHER | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06433752 |
| No intervention | OTHER | Preclinical | Relapsing Multiple Sclerosis | RECRUITING | NCT06143514 |
| Acalabrutinib | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04624633 |
| Acalabrutinib Oral Capsule | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT04016805 |
| TG-1801 | BIOLOGICAL | Phase PHASE1 | CLL | TERMINATED | NCT04806035 |
| Cosibelimab + Ublituximab + Bendamustine combination | DRUG | Phase PHASE1 | B-cell Non Hodgkin Lymphoma | TERMINATED | NCT03778073 |
| Cosibelimab | DRUG | Phase PHASE1 | B-cell Non Hodgkin Lymphoma | TERMINATED | NCT03778073 |
| Pembrolizumab | BIOLOGICAL | Phase PHASE2 | Hodgkin's Lymphoma | TERMINATED | NCT03776864 |
| TG-1701 | DRUG | Phase PHASE1 | Non Hodgkin Lymphoma | TERMINATED | NCT03671590 |
| Venetoclax | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT04016805 |
| IV Placebo | DRUG | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | COMPLETED | NCT03277261 |
| Oral Placebo | DRUG | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | COMPLETED | NCT03277261 |
| Teriflunomide | DRUG | Phase PHASE3 | Relapsing Multiple Sclerosis (RMS) | COMPLETED | NCT03277261 |
| TGR-1202 + Ublituximab | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT03207256 |
| Bendamustine | BIOLOGICAL | Phase PHASE2 | Diffuse Large B-Cell Lymphoma | TERMINATED | NCT02793583 |
| Placebo | DRUG | Phase PHASE2 | Relapsing Multiple Sclerosis | NOT_YET_RECRUITING | NCT07220252 |
| Chlorambucil | DRUG | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT02612311 |
| Obinutuzumab | BIOLOGICAL | Phase PHASE3 | Chronic Lymphocytic Leukemia | TERMINATED | NCT02612311 |
| Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab | DRUG | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02574663 |
| Oxaliplatin + Folinic acid + Fluorouracil | DRUG | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02574663 |
| nab-paclitaxel + gemcitabine | DRUG | Phase PHASE1 | Pancreatic Cancer | COMPLETED | NCT02574663 |
| TG-1501 | BIOLOGICAL | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02535286 |
| ublituximab | BIOLOGICAL | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02535286 |
| Umbralisib | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04624633 |
| TGR-1202 + brentuximab vedotin | DRUG | Phase PHASE1 | Hodgkin's Lymphoma | COMPLETED | NCT02164006 |
| Ibrutinib | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT04016805 |
| TGR-1202 + Obinutuzumab + Chlorambucil | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02100852 |
| Ublituximab + TGR-1202 + bendamustine | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02006485 |
| Ublituximab + TGR-1202 + ibrutinib | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02006485 |
| Ublituximab + TGR-1202 | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT02006485 |
| TGR-1202 | DRUG | Phase PHASE2 | Chronic Lymphocytic Leukemia | TERMINATED | NCT03207256 |
| Lenalidomide | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT03379051 |
| Ublituximab | DRUG | Phase PHASE2 | Multiple Sclerosis | NOT_YET_RECRUITING | NCT07503873 |
Total products: 293